FDA Advisers Recommend New RSV Vaccine for Infants and Pregnant Women.

The US FDA's independent vaccine advisers have voted in favor of recommending approval of Pfizer's new vaccine to protect infants from respiratory syncytial virus (RSV), which is the leading cause of child hospitalizations in the US. The maternal vaccine is a single-dose shot given to pregnant people late in pregnancy, which triggers the development of antibodies that are passed on to the fetus and provide protection for about the first 6 months of the baby's life. Trials show that the vaccine cuts the risk that infants would need to see a doctor or be admitted to the hospital with a moderate to severe infection.